Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

Afkhami, Sam; D’Agostino, Michael R.; Zhang, Ali; Stacey, Hannah D.; Marzok, Art; Kang, Alisha; Singh, Ramandeep; Bavananthasivam, Jegarubee; Ye, Gluke; Luo, Xiangqian; Wang, Fuan; Ang, Jann C.; Zganiacz, Anna; Sankar, Uma; Kazhdan, Natallia; Koenig, Joshua F. E.; Phelps, Allyssa; Gameiro, Steven F.; Tang, Shangguo; Jordana, Manel; Wan, Yonghong; Mossman, Karen L.; Jeyanathan, Mangalakumari; Gillgrass, Amy; Medina, Maria Fe C.; Smaill, Fiona; Lichty, Brian D.; Miller, Matthew S.; Xing, Zhou

doi:10.1016/j.cell.2022.02.005

Javascript is disabled or not supported in your browser. JavaScript must be enabled in order for you to use WIKINDX fully. Enable JavaScript through your browser options then try again, otherwise, try using a different browser.

BioAcyl Corp

WIKINDX Resources

Afkhami, S., D’Agostino, M. R., Zhang, A., Stacey, H. D., Marzok, A., & Kang, A., et al. (2022). Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell.
Added by: Dr. Enrique Feoli (11/02/2022, 17:27) Last edited by: Dr. Enrique Feoli (11/02/2022, 18:59)

Resource type: Journal Article
DOI: 10.1016/j.cell.2022.02.005
ID no. (ISBN etc.): 0092-8674, 1097-4172
BibTeX citation key: Afkhami2022
View all bibliographic details

Categories: BioAcyl Corp, BioAcyl Corp
Subcategories: Covid-19 adenoviral vectors, COVID-19 Vaccines
Creators: Afkhami, Ang, Bavananthasivam, D’Agostino, Gameiro, Gillgrass, Jeyanathan, Jordana, Kang, Kazhdan, Koenig, Lichty, Luo, Marzok, Medina, Miller, Mossman, Phelps, Sankar, Singh, Smaill, Stacey, Tang, Wan, Wang, Xing, Ye, Zganiacz, Zhang
Collection: Cell

Views: 4/445

Abstract

The emerging SARS-CoV-2 variants of concern (VOC) threaten the effectiveness of current COVID-19 vaccines administered intramuscularly and designed to only target the spike protein. There is a pressing need to develop next-generation vaccine strategies for broader and long-lasting protection. Using adenoviral vectors (Ad) of human and chimpanzee origin, we evaluated Ad-vectored trivalent COVID-19 vaccines expressing Spike-1, Nucleocapsid and RdRp antigens in murine models. We show that single-dose intranasal immunization, particularly with chimpanzee Ad-vectored vaccine, is superior to intramuscular immunization in induction of the tripartite protective immunity consisting of local and systemic antibody responses, mucosal tissue-resident memory T cells and mucosal trained innate immunity. We further show that intranasal immunization provides protection against both the ancestral SARS-CoV-2 and two VOC, B.1.1.7 and B.1.351. Our findings indicate that respiratory mucosal delivery of Ad-vectored multivalent vaccine represents an effective next-generation COVID-19 vaccine strategy to induce all-around mucosal immunity against current and future VOC.
Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli

Notes

Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli